Track topics on Twitter Track topics that are important to you
SANTA FE, N.M., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Sigma Labs, Inc. (OTCQB:SGLB) ("Sigma Labs" or the "Company"), a developer of advanced, in process, non-destructive quality inspection systems for metal-based additive manufacturing ("AM") and other advanced manufacturing technologies, today announced financial results for the three and six months ended June 30, 2015.
"Sigma Labs noted some significant achievements this quarter, although revenue was less than anticipated due to delays with respect to our contract with GE Aviation as part of the America Makes program," said Mark Cola, President and CEO of Sigma Labs. "This $500,000 award is now moving forward, and we are optimistic about seeing a portion of this revenue bolster our growth in the second half of 2015. At the same time, I'm very pleased to announce the hiring of Ron Fisher as Sigma Labs' Vice President of Business Development. Ron brings over 20 years' experience and leadership in program management, engineering, sales and marketing from a variety of manufacturing institutions including Swagelok and Micro-Poise Measurement Systems. At Sigma Labs, Ron will be responsible for the sales and administration of everything related to PrintRite3D®.
"With Ron's addition, and with Bill Herman heading up our contract manufacturing operations under our new joint venture, the Company is in a better position to demonstrate its full capabilities and accelerate top line growth. We've also contracted some additional staff to finalize our ground-breaking DEFORM™ application, which we now expect to be commercially available by October 2015. So while we've faced some unfortunate delays recently, Sigma Labs is actually on better footing than ever to execute its expansion plans and drive towards profitability. I'm excited about what the future holds for the Company."
2015 Second Quarter Financial Results
Service revenue for the three and six months ended June 30, 2015 was approximately $0.2 million and $0.4 million, respectively, versus approximately $0.1 million and $0.2 million for the same periods in 2014. The Company reported a net loss for the three and six months ended June 30, 2015 of approximately $0.4 million and $0.8 million, respectively, or $(0.00) per diluted share, versus a loss of approximately $1.8 million and $2.3 million, or $(0.00) per diluted share, for the same periods in 2014. The prior-year period included a nonrecurring warrant expense of approximately $1.3 million.
Investor Conference Call
The Company will host a conference call to discuss its 2015 second quarter financial results today, August 7, 2015, at 11:00 a.m. Eastern Time. To participate in the call, please dial toll free 1-888-243-4451, or 1-412-542-4135, approximately five minutes before the conference call time stated. A live webcast of the call can also be accessed on the Sigma Labs website at www.sigmalabsinc.com. A recording will be available on the Company's website upon completion of the call.
About Sigma Labs, Inc.
Sigma Labs, Inc., through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3D printing, and other advanced manufacturing technologies. For more information please visit us at www.sigmalabsinc.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in our most recent annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.
|Sigma Labs, Inc. and Subsidiary|
|Unaudited Condensed Consolidated Statements of Operations|
|Three Months and Six Months Ended June 30, 2015 and 2014|
|Three Months Ended||Six Months Ended|
|June 30, 2015||June 30, 2014||June 30, 2015||June 30, 2014|
|Services||$ 196,263||$ 114,813||$ 381,949||$ 229,642|
|COST OF SERVICE REVENUE||88,262||84,739||113,129||140,628|
|Other General and Administration||326,075||135,651||593,778||315,047|
|Non-cash Stock Compensation||134,250||326,200||257,000||351,400|
|Research and Development||13,881||30,985||84,028||101,132|
|OTHER INCOME (EXPENSE)|
|Total Other Income (Expense)||312||940||872||1,782|
|INCOME (LOSS) BEFORE INCOME TAXES||(440,367)||(1,795,909)||(812,248)||(2,262,815)|
|Current Income Tax Expense||--||--||--||--|
|Deferred Income Tax Expense||--||--||--||--|
|Net Income (Loss)||$ (440,367)||$ (1,795,909)||$ (812,248)||$ (2,262,815)|
|Loss per Common Share - Basic and Diluted||$ (0.00)||$ (0.00)||$ (0.00)||$ (0.00)|
|Weighted Average Number of Shares|
|Outstanding - Basic and Diluted||623,344,835||606,743,259||621,990,931||602,814,680|
|Sigma Labs, Inc. and Subsidiary|
|Condensed Consolidated Balance Sheets|
|June 30, 2015 and December 31, 2014|
|June 30, 2015||December 31, 2014|
|Cash||$ 2,224,318||$ 2,962,069|
|Accounts Receivable, net||127,961||117,726|
|Total Current Assets||2,486,992||3,165,956|
|Property and Equipment, net||739,802||803,027|
|Deferred Stock Offering Costs||95,511||95,511|
|Intangible Assets, net||96,040||95,847|
|Total Other Assets||931,353||994,385|
|TOTAL ASSETS||$ 3,418,345||$ 4,160,341|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts Payable||$ 95,675||$ 309,698|
|Total Current Liabilities||144,902||354,350|
|Preferred Stock, $0.001 par; 10,000,000 shares authorized;|
|None issued and outstanding||--||--|
|Common Stock, $0.001 par; 750,000,000 shares authorized;|
|623,344,835 issued and 617,292,949|
|outstanding at June 30, 2015 and|
|619,741,061 issued and 612,741,061|
|outstanding at December 31, 2014||623,345||619,741|
|Additional Paid-In Capital||9,985,684||9,798,288|
|Less Deferred Compensation|
|6,051,886 and 7,000,000 common shares, respectively||(655,500)||(744,200)|
|Retained Earnings (Deficit)||(6,680,086)||(5,867,838)|
|Total Stockholders' Equity||3,273,443||3,805,991|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY||$ 3,418,345||$ 4,160,341|
CONTACT: Investor Relations Contact: Chris Witty firstname.lastname@example.org 646-438-9385NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...